Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Development of a humanized mouse model with functional human materno-fetal interface immunity
Shuai Dong, … , Yong-Guang Yang, Zheng Hu
Shuai Dong, … , Yong-Guang Yang, Zheng Hu
Published October 22, 2024
Citation Information: JCI Insight. 2024;9(20):e176527. https://doi.org/10.1172/jci.insight.176527.
View: Text | PDF
Research Article Immunology Reproductive biology

Development of a humanized mouse model with functional human materno-fetal interface immunity

  • Text
  • PDF
Abstract

Materno-fetal immunity possesses specialized characteristics to ensure pathogen clearance while maintaining tolerance to the semiallogeneic fetus. Most of our understanding on human materno-fetal immunity is based on conventional rodent models that may not precisely represent human immunological processes owing to the huge evolutionary divergence. Herein, we developed a pregnant human immune system (HIS) mouse model through busulfan preconditioning, which hosts multilineage human immune subset reconstitution at the materno-fetal interface. Human materno-fetal immunity exhibits a tolerogenic feature at the midgestation stage (embryonic day [E] 14.5), and human immune regulatory subsets were detected in the decidua. However, the immune system switches to an inflammatory profile at the late gestation stage (E19). A cell–cell interaction network contributing to the alternations in the human materno-fetal immune atmosphere was revealed based on single-cell RNA-Seq analysis, wherein human macrophages played crucial roles by secreting several immune regulatory mediators. Furthermore, depletion of Treg cells at E2.5 and E5.5 resulted in severe inflammation and fetus rejection. Collectively, these results demonstrate that the pregnant HIS mouse model permits the development of functional human materno-fetal immunity and offers a tool for human materno-fetal immunity investigation to facilitate drug discovery for reproductive disorders.

Authors

Shuai Dong, Cong Fu, Chang Shu, Min Xie, Yan Li, Jun Zou, Yi-Zi Meng, Peng Xu, Yan-Hong Shan, Hui-Min Tian, Jin He, Yong-Guang Yang, Zheng Hu

×

Figure 5

Inhibition of human Treg cells causes pregnancy termination and fetal rejection in pregnant HIS mice.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of human Treg cells causes pregnancy termination and fetal re...
Treg cell inhibitory function examination. (A) Summarized data (n = 3; mean ± SEM) of the immune-inhibitory effect of human dTreg or sTreg cells on human sTconv cell proliferation in the presence of 30 Gy–irradiated BALB/c splenic cells. Representative FCM profiles of Tconv cell proliferation. Treg/Tconv = 1:16, BALB/c stimulator cells/Tconv = 1:2. Statistical differences were determined with 1-way ANOVA for multiple-variable comparisons. (B) Schematic outline of the experimental design. Anti-CD25 mAb (basiliximab; n = 6) or equal volume of PBS (n = 5) was i.p. injected into pregnant HIS mice (200 μg/mouse) made by mating with BALB/c males at E2.5 and E5.5, and the mice were euthanized at E14.5. Percentages (mean ± SEM, C) and representative FCM profiles (D) of Treg cells after anti-CD25 mAb injection were shown. Statistical analyses were performed using unpaired t test. (E) The number of implantation sites of pregnant HIS mice treated with PBS (n = 5) or basiliximab (n = 6). Statistical differences were calculated with 2-way ANOVA. (F) Representative photos of the uteri harvested from HIS mice treated with basiliximab (upper panel) or PBS (lower panel).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts